Stay updated on Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial
Sign up to get notified when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.

Latest updates to the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference1.0%
- Check16 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
- Check24 days agoNo Change Detected
- Check60 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check74 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact for assistance.SummaryDifference5%
- Check81 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
- Check96 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
Stay in the know with updates to Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.